NASDAQ:MDXG - MiMedx Group Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.50
  • Forecasted Upside: 105.31 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.14
▲ +0.14 (3.50%)

This chart shows the closing price for MDXG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MiMedx Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDXG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDXG

Analyst Price Target is $8.50
▲ +105.31% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for MiMedx Group in the last 3 months. The average price target is $8.50, with a high forecast of $8.50 and a low forecast of $8.50. The average price target represents a 105.31% upside from the last price of $4.14.

This chart shows the closing price for MDXG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in MiMedx Group.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2021HC WainwrightReiterated RatingBuy$8.50Low
9/14/2021HC WainwrightLower Price TargetBuy$20.00 ➝ $8.50High
7/26/2021Northland SecuritiesInitiated CoverageOutperform$23.00Medium
3/19/2021HC WainwrightInitiated CoverageBuy$20.00High
3/15/2018Needham & Company LLCReiterated RatingHoldHigh
2/27/2018Craig HallumReiterated RatingBuyLow
2/23/2018Lake Street CapitalDowngradeBuy ➝ Hold$9.00Low
2/21/2018Lake Street CapitalSet Price TargetBuy$18.00 ➝ $12.00Low
2/20/2018Needham & Company LLCDowngradeStrong-Buy ➝ HoldHigh
12/14/2017Lake Street CapitalSet Price TargetBuy$18.00Low
12/1/2017Piper Jaffray CompaniesReiterated RatingBuy$18.00Low
12/1/2017Needham & Company LLCReiterated RatingBuy$21.00Low
11/24/2017Piper Jaffray CompaniesReiterated RatingBuy$18.00Medium
11/14/2017Needham & Company LLCReiterated RatingBuy$21.00N/A
10/30/2017Needham & Company LLCReiterated RatingBuy$21.00N/A
9/5/2017Needham & Company LLCBoost Price TargetStrong-Buy ➝ Strong-Buy$20.00 ➝ $21.00Low
8/20/2017Piper Jaffray CompaniesReiterated RatingBuy$18.00Low
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/14/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/13/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/15/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2022
  • 6 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/13/2022
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2022
  • 4 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
8/12/2022

Current Sentiment

  • 4 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
MiMedx Group logo
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Read More

Today's Range

Now: $4.14
Low: $3.95
High: $4.21

50 Day Range

MA: $3.61
Low: $3.17
High: $4.19

52 Week Range

Now: $4.14
Low: $3.04
High: $8.69

Volume

475,419 shs

Average Volume

542,098 shs

Market Capitalization

$470.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.79

Frequently Asked Questions

What sell-side analysts currently cover shares of MiMedx Group?

The following equities research analysts have issued reports on MiMedx Group in the last year: HC Wainwright, and StockNews.com.
View the latest analyst ratings for MDXG.

What is the current price target for MiMedx Group?

1 Wall Street analysts have set twelve-month price targets for MiMedx Group in the last year. Their average twelve-month price target is $8.50, suggesting a possible upside of 105.3%. HC Wainwright has the highest price target set, predicting MDXG will reach $8.50 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.50 for MiMedx Group in the next year.
View the latest price targets for MDXG.

What is the current consensus analyst rating for MiMedx Group?

MiMedx Group currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDXG will outperform the market and that investors should add to their positions of MiMedx Group.
View the latest ratings for MDXG.

What other companies compete with MiMedx Group?

Other companies that are similar to MiMedx Group include Sight Sciences, IRadimed, Orthofix Medical, Surmodics and SI-BONE. Learn More about companies similar to MiMedx Group.

How do I contact MiMedx Group's investor relations team?

MiMedx Group's physical mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The company's listed phone number is (770) 651-9100 and its investor relations email address is [email protected] The official website for MiMedx Group is www.mimedx.com. Learn More about contacing MiMedx Group investor relations.